| Autor: |
Iswar Raja V, Ghokilavani R, Nivethitha M, Shruthi R, Merin T Koshy |
| Rok vydání: |
2023 |
| Předmět: |
|
| DOI: |
10.5281/zenodo.8108754 |
| Popis: |
Background: Antipsychotic drugs are used in treatment of psychological and neurological disorders. The major side effect of these drugs is weight gain. Metformin has been evaluated to prevent or reduce weight gain. Our aim of the study is to conduct a systematic review on metformin for the treatment of anti-psychotics induced weight gain.Main Body of the Abstract: The primary objective of this review was to evaluate the safety and efficacy of metformin for the treatment of antipsychotics induced weight gain. A systematic review and meta-analysis were conducted with various articles collected in source of original articles through databases like PubMed, Embase, MEDLINE, BMC psychiatry etc. Articles associated with metformin in weight loss for patients with anti- psychotics induced weight gain were included and articles with other interventions were excluded. As a result of total of 257 articles were screened in total and 33 articles were systemically reviewed andarticles were meta-analysed. The risk of bias assessment was done using Cochrane’s Risk of bias assessment tool. Meta- analysis was carried out. The forest plot was made using RevMan Software (Version 5.3; Cochrane Collaboration). The studies assessed the effectiveness of the metformin when compared to the control intervention at several time points. The differences between pre and post measurements were calculated in each arm and differences across treatment and control group was taken as the measure. Heterogeneity was quantified by I 2 statistic.Conclusion: The systematic review and meta-analysis concludes that metformin is highly effective in the treatment of patient with anti-psychotics induced weight gain and safe in long term use up to 6 months as it was able to reducethe weight of patients on metformin ranging from 3 to 5 kgs. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
